Atlas Trials

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Clinical trial NCT00980018 · COMPLETED

Trial details

NCT number
NCT00980018
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Chronic Myelogenous Leukemia
Start date
2009-12-01
Primary completion
2012-12-01
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.